Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）

Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment.
The concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolutionized the diagnosis and management of EC. EC subtypes with distinct molecular features demonstrate substantial differences in biological behaviors and responses to pharmacotherapeutic interventions. Nevertheless, the role of molecular subtyping in guiding FST decision-making-both in terms of its applicability and specific mechanisms-remains an unmet research need worldwide.
Notably, the POLE-mutant and microsatellite instability-high (MSI-H) subtypes display the highest sensitivity to immune checkpoint inhibitors, underscoring the clinical value of exploring their utility in FST. The no specific molecular profile (NSMP) subtype is sensitive to progestogens but lacks reliable predictive biomarkers-accurate pre-treatment prediction would enable tailored treatment selection, shorten treatment duration, and enhance therapeutic outcomes. In contrast, the p53-abnormal (p53abn) subtype is associated with a poor prognosis, and FST is therefore not recommended for this subgroup.
Building on the aforementioned background and our research team's preliminary clinical findings, this project focuses on the field of FST for EC. To address the current challenges-including narrow indications, limited treatment options, suboptimal efficacy, and the absence of precise personalized regimens-we aim to conduct the world's first prospective multicenter umbrella trial based on EC molecular subtyping. Optimal novel diagnostic and therapeutic protocols will be developed for each molecular subtype, with the goals of optimizing existing FST strategies, improving FST efficacy and reproductive outcomes, expanding eligible indications, and providing high-quality clinical evidence for molecular subtype-guided FST in EC, thereby advancing the overall effectiveness of FST for EC patients.

Start Date15 Dec 2025

Sponsor / Collaborator

Fudan University

IRCT20250225064853N5

/ SuspendedPhase 3IIT

Evaluating the Effect of Medroxyprogesterone on Reducing Size and Symptoms of Endometrial Polyps in Patients with Endometrial Polyps: A Randomized Controlled Trial with Placebo Group

Start Date21 Nov 2025

Sponsor / Collaborator

Isfahan University of Medical Sciences

CTR20253621

/ RecruitingPhase 3

一项评价瑞卢戈利片治疗子宫肌瘤导致月经过多的有效性和安全性的多中心、随机、双盲、安慰剂对照临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of relugolix tablets in the treatment of menorrhagia caused by uterine fibroids

评价瑞卢戈利片40mg治疗子宫肌瘤导致月经过多的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of relugolix tablets 40 mg in the treatment of menorrhagia caused by uterine fibroids.

Start Date07 Nov 2025

Sponsor / Collaborator

Brilliant Pharmaceutical Co. Ltd.

100 Clinical Results associated with Medroxyprogesterone Acetate

100 Translational Medicine associated with Medroxyprogesterone Acetate

100 Patents (Medical) associated with Medroxyprogesterone Acetate

6,784

Literatures (Medical) associated with Medroxyprogesterone Acetate

31 Dec 2026·Human Fertility

Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol

Article

Author: Sherlock, K. ; Kastora, S. ; Alabi, C. ; Vaughan, E. ; Yasmin, E. ; Lavery, S. ; Balachandren, N. ; Atik, Y. ; Davies, M. C.

Suppression of an LH surge is fundamental to successful oocyte retrieval after controlled ovarian stimulation. This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles. The design is a retrospective single-centre study (January 2022-August 2023) comparing two ovarian stimulation protocols: PPOS and the gonadotrophin-releasing hormone antagonist (GnRHant) protocols. Cycles began at any time of the menstrual cycle. The primary outcome was the number of metaphase II oocytes retrieved. Secondary outcomes included total oocytes retrieved, maturity ratio, stimulation duration, incidence of premature LH rise/ovulation events, and the cost of medication used to prevent ovulation. The study included 125 fertility preservation cycles: 54 in the PPOS group and 71 in the GnRHant group. Median body mass index, antral follicle count, and anti-Mullerian hormone levels were comparable between the two groups. The median age was younger in the PPOS group; 28 years vs. 32 years, p = 0.03. Mature oocyte retrieval was similar; mean 9.33 [SD 5.87] vs. 8.97 [SD 5.44], p = 0.73. No premature LH rises occurred in either group. Secondary outcomes showed no significant differences, except for the cost of medication used to prevent ovulation. The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol.

01 Apr 2026·DOMESTIC ANIMAL ENDOCRINOLOGY

Functional luteal tissue formation and progesterone production following preovulatory follicle aspiration and follicular cell restoration in ewes

Article

Author: Silva, Nuno Emanuel Oliveira Figueiredo ; Oba, Eunice ; Kastelic, John Patrick ; Watanabe, Yeda Fumie ; Franchi, Fernanda Fagali ; da Rocha, Paula Barreto ; Ferreira, João Carlos Pinheiro ; Garcia, Rodrigo ; Denadai, Renan ; Salgado, Leticia Cristina ; Bicudo, Sony Dimas

The objective was to monitor corpus luteum (CL) development after preovulatory follicle aspiration, with or without intrafollicular autologous follicular cell restoration. Eighteen ewes were synchronized by inserting an intravaginal pessary with 60 mg medroxyprogesterone acetate on day -16, inducing luteolysis with cloprostenol (140 µg, im) on day -12, followed by pessary withdrawal and equine chorionic gonadotropin (400 IU, im) on day -2. Forty-eight hours later, ewes were assigned to Control (CO; n = 5), Laparoscopic aspiration (LA; n = 6), or Laparoscopic aspiration + follicular cell restoration (FCR; n = 7) treatments. Daily ultrasonography assessed the largest individual CL cross-sectional area (CLA) and total luteal sectional area (TLA), and blood samples were collected every 48 h to assess plasma progesterone concentrations. Luteal formation was observed in all ewes. However, the LA group exhibited a higher number of CLs compared to the CO group (1.7 ± 0.5 vs. 1.0 ± 0.0; P < 0.05). Nevertheless, neither CO nor LA differed from the FCR group (1.4 ± 0.2; P = 0.10 and P = 0.60, respectively). In addition, TLA values were similar among the CO, LA, and FCR groups (0.8 ± 0.04, 0.9 ± 0.05, and 1.0 ± 0.05 cm², respectively; P = 0.50) and plasma progesterone concentrations did not differ significantly (4.0 ± 0.31, 3.7 ± 0.30, and 2.9 ± 0.30 ng/mL, respectively; P = 0.30). In conclusion, preovulatory follicle aspiration induces luteal tissue formation, which, with or without intrafollicular autologous follicular cell restoration, results in functional CL capable of producing progesterone levels consistent with those normally observed during the estrous cycle.

28 Feb 2026·FASEB JOURNAL

Establishment and Functional Characterization of Bovine Endometrial Epithelial Organoids

Article

Author: Vourekas, Anastasios ; Loux, Shavahn C. ; Fuego, Dailin M. ; Simintiras, Constantine A. ; Devkota, Iebu ; Bondioli, Kenneth R. ; Bonomo, Zachary L. ; Elzer, Philip H. ; Zhang, Xujia ; Fu, Xing ; Li, Yuxia ; Matsakas, Antonios ; Looney, Charles R. ; Bermejo‐Álvarez, Pablo ; Bromfield, John J. ; Maia, Ana I. V. ; Donnarumma, Fabrizio

ABSTRACT:

Pre‐implantation embryonic loss constitutes a major barrier to reproductive efficiency in livestock, yet the extrinsic determinants of embryonic survival remain poorly defined. Intra‐organoid fluid (IOF) faithfully recapitulates native tissue secretions across multiple organ systems. We hypothesized that bovine endometrial epithelial organoids (BEEO) would produce IOF that mirrored in vivo uterine luminal fluid composition and extend embryo culture duration in vitro. We pursued three objectives: (a) establish and morphologically characterize BEEO, (b) define BEEO transcriptomic and secretory responses to 17β‐estradiol (E2), medroxyprogesterone acetate (MPA), and interferon‐tau (IFNτ), and (c) determine whether BEEO‐derived IOF can support in vitro embryonic development beyond Day 8 (hatched blastocyst stage) under conventional culture conditions. BEEO were established from primary endometrial tissue ( n = 4) and maintained a stable epithelial phenotype through multiple passages. Transcriptomic profiling revealed robust responses to stimulation, with E2, MPA, and IFNτ inducing distinct gene expression programs consistent with in vivo effects. IOF metabolomic analysis confirmed hormone‐dependent regulation of IOF secretory output, with E2 + MPA (diestrus mimic) enhancing the production of metabolites implicated in conceptus development. Remarkably, IOF from diestrus mimic‐stimulated BEEO, despite being diluted approximately seven‐fold in PBS, maintained embryo survival rates comparable to optimized commercial medium and exceeded PBS‐only controls. These findings position BEEO as a physiologically relevant model for dissecting maternal‐embryo interactions in vitro and identifying targets to improve fertility in cattle and other livestock.

News (Medical) associated with Medroxyprogesterone Acetate

12 Jan 2026

·www.drugs.com

A Self-Injectable Birth Control Med Is Available, But Most Doctors Don't Prescribe It

MONDAY, Jan. 12, 2026 — Young women could be injecting long-lasting birth control meds themselves, but few have been told by their doctor that it’s an option, a new study says. Depot medroxyprogesterone acetate (DMPA) can prevent pregnancy for up to three months, and is available in a form that can be self-injected under the skin, researchers reported in the February issue of the journal Obstetrics & Gynecology . But only a third of doctors who regularly prescribe birth control offer this option, even though most know about it, researchers found. “It’s safe, effective and puts the control in patients’ own hands,” senior researcher Dr. Jennifer Karlin , an associate professor of family and community medicine at the University of California-San Francisco, said in a news release. “We should be talking about and offering it to patients without biases.” DMPA is available in two injectable forms, researchers said. One, an intramuscular injection, is sold under the name Depo-Provera and can only be administered by a health care provider. But the other form can be easily self-injected, in the same way that GLP-1 weight loss drugs are taken, researchers said. This self-injectable version was approved in 2004 and is officially labeled for administration by a clinician, but doctors have been training patients to self-inject the drug safely for years, researchers said. It became more widely used in the U.S. during the COVID pandemic, researchers said. For the new study, researchers surveyed more than 400 doctors and found that 3 in 4 (75%) were aware that this version of DMPA is available. More than half learned about this option between 2020 and 2022, during the pandemic. However, only 35% actively prescribe this option to patients, the survey found. Doctors surveyed expressed concerns about their patients’ ability to self-inject, the medication’s availability at pharmacies, and the lack of standardized approaches to counsel patients or prescribe the drug, researchers said. Doctors with a background in reproductive medicine or who treat more young women were more likely to know of the self-injectable DMPA option, the survey found. On the other hand, doctors in states with restrictions on abortion access were less likely to prescribe it. Researchers recommended an education campaign to make doctors aware of these self-administered injectable contraceptives, and for the U.S. Food and Drug Administration (FDA) to approve a version of this self-injectable drug. “FDA approval for DMPA-SC for self-administration is a key policy and system-level barrier,” researchers wrote. “Approval would increase professional confidence and expand insurance coverage, reducing economic barriers. Increased demand through expanded prescribing could also improve pharmacy stock availability, further enhancing access.” Sources University of California-San Francisco, news release, Jan. 8, 2026 Obstetrics & Gynecology, February 2026

Drug Approval

07 Jan 2026

·www.einpresswire.com

Vigna Law Group: Depo-Provera Meningioma Claim Filed in Alameda County, California

Medical literature links continued Depo-Provera use after meningioma resection to higher recurrence, raising physician and manufacturer liability concerns We filed this case because drug was not only prescribed before our client's meningioma diagnosis, but also continued after surgical removal of the tumor.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, January 7, 2026 / EINPresswire.com / -- “At some point, physicians can be held liable for prescribing Depo-Provera when there are alternative birth control medications that do not cause mutations that lead to brain tumors. The literature on this is clear,” states Greg Vigna, MD, JD, national malpractice, Depo-Provera attorney. Dr. Greg Vigna, MD, JD, says, “We filed this case because drug was not only prescribed before our client's meningioma diagnosis, but also continued after surgical removal of the tumor. We allege that our client’s injuries were further exacerbated by the ongoing prescription, resulting in additional harm." (Case: 25CV151521, Superior Court of the State of California for the County of Alameda). Dr. Vigna continues, “Clearly, women who are newly diagnosed and have a history of recent use should have their cases closely reviewed to determine whether their claims may be more appropriately filed against both the prescribing physician and the manufacturer of Depo-Provera or an authorized generic in state court where the injury occurred.“ What does the literature say about continued use of Depo-Provera after resection? Read Dr. Tessa Harland's report in “Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma” published in the Journal of Neuro-oncology (2018) 136:327-333?: "Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a reduced time to recurrence (18 vs. 32 months, p = 0.038) … those taking progesterone-only contraception.” Read Dr. Harland’s article here . Dr. Vigna concludes, “There have always been safer medications for contraception than Depo-Provera. This is a drug that causes specific mutations to women’s DNA." Watch Dr. Vigna’s educational episode on Justice with Dr. V for an in-depth look at the association of Depo-Provera and Meningiomas. Click here to watch Justice with Dr. V on Tik Tok to learn more on Depo-Provera. Dr. Vigna is a California and Washington DC lawyer and is Co-Counsel with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent women who have suffered meningiomas. To learn more, visit https://vignalawgroup.com/practice-area/meningioma-resection/ . Case: 25CV151521 Superior Court of the State of California for the County of Alameda California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street,2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 817-809-9023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent Infringement

06 Jan 2026

·www.einpresswire.com

Pfizer Joined in a Depo-Provera Meningioma Case in California State Court

The literature indicates that Depo-Provera is mutagenic, and there are alternative birth control options that are as effective but not mutagenic and do not carry the same risk of causing meningiomas.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, January 5, 2026 / EINPresswire.com / -- “Pfizer, to this day, does not disclose in its warnings that Depo-Provera is mutagenic, despite clear evidence of a dose-dependent increased risk of meningiomas in women injected with the drug for one year or more, and evidence of a specific mutational tendency associated with its use,” states Greg Vigna, MD, JD, national neurological injury attorney. Dr. Greg Vigna, MD, JD, states, "Pfizer is now involved in a significant legal case in California State Court in Alameda County regarding the known increased risk of meningiomas linked to Depo-Provera. The alleged negligence of the prescribing physician centers on their failure to discontinue Depo-Provera or Medroxyprogesterone after our client was diagnosed with a cerebral meningioma, which we contend led to a recurrence of the meningioma after resection, now resulting in multiple meningiomas. The literature clearly indicates that this drug is mutagenic, and there are alternative birth control options that are equally effective but not mutagenic and do not carry the same risk of causing meningiomas.” What is a mutagen as defined by Merriam-Webster? “An agent as a chemical that tends to increase the frequency or extent of mutation." Read the definition: https://www.merriam-webster.com/dictionary/mutagenic . Dr. Vigna states, “The 2024 Roland study supports that this drug is mutagenic as it increases the risk of meningiomas in women who were prescribed Depo-Provera or Medroxyprogesterone for one year or more. Roland and the 2018 study by Petrye describe how Depo-Provera or Medroxyprogesterone can cause a mutational shift in meningiomas, leading to a tendency for multiple tumors at the skull base, as well as an overall increased frequency of meningiomas." Read Roland's article: https://www-bmj-com.libproxy1.nus.edu.sg/content/bmj/384/bmj-2023-078078.full.pdf Read Peyre's article . Dr. Vigna concludes, “We review each case individually to determine whether a woman's claim might be more appropriately filed in the state where the medication was prescribed, rather than in the consolidated Florida litigation, which currently has over a thousand cases. It is important to understand why physicians are prescribing Depo-Provera and Medroxyprogesterone despite the extensive literature linking these drugs to serious injuries, especially when alternative birth control medications exist that do not carry a risk of causing meningiomas.” Vigna Law Group is a national litigation firm that focuses on neurological injuries caused by medical malpractice, mid-urethral slings, and harmful drugs, including Depo-Provera. He represents women with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent neurological injuries across the country. Learn more: https://vignalawgroup.com/practice-area/meningioma-resection/ Watch Dr. Vigna’s episode on Depo-Provera. Click here to watch Dr. Vigna’s Tik Tok for more information on Depo-Provera. California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street,2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 8178099023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent Infringement

100 Deals associated with Medroxyprogesterone Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00951	Medroxyprogesterone Acetate	L02AB02 G03AC06 G03DA02	DB00603

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Suppression of ovulation	Japan	Kyowa Kirin Co., Ltd.	11 Mar 2022
Pain	United States	Pfizer Inc.	04 Dec 2020
Contraception	United States	Pfizer Inc.	17 Dec 2004
Pregnancy	United States	Pfizer Inc.	29 Oct 1992
Breast Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Endometrial Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Prostatic Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Renal Cell Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Abortion, Habitual	Japan	Pfizer Japan, Inc.	25 Jan 1963
Abortion, Threatened	Japan	Pfizer Japan, Inc.	25 Jan 1963
Hypomenorrhea	Japan	Pfizer Japan, Inc.	25 Jan 1963
Infertility	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menorrhagia	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menstruation Disturbances	Japan	Pfizer Japan, Inc.	25 Jan 1963
Amenorrhea	United States	Pfizer Inc.	18 Jun 1959
Endometrial Hyperplasia	United States	Pfizer Inc.	18 Jun 1959
Metrorrhagia	United States	Pfizer Inc.	18 Jun 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Eczema	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Neurodermatitis	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Osteoporosis, Postmenopausal	Phase 1	-	Wyeth AB	01 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05726903 (CTgov)	Phase 4	-	35	Depo-subQ Provera	bjndorlhwc(zomaovbqaa) = rvsosjdthi gdkvjeeinw (ojbwgetijh, zveebydcxt - fczkcbpmrh) View more	-	12 Feb 2026
NCT04669678 (EPIC, CTgov)	Phase 4	Medication interactions \| HIV Infections \| Contraception	110	Etonogestrel (Group 1 DOR + ETG)	bujxwjetsh(cwaiebvhmo) = glkyaozwca sdpzznybei (vvrdzscezu, ywoeihfszl - slqsfsfuqc) View more	-	08 Apr 2025
				Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (Group 2 DOR + IM DMPA)	bujxwjetsh(cwaiebvhmo) = fbhpuepune sdpzznybei (vvrdzscezu, kqoxtuurgv - vzymjvmaii) View more
NCMP-03 (SNO2024)	Not Applicable	Meningioma ER/PR	64	EstrogenroneProgesteroneon (Estrogen or Progesterone use)	ktwcahgfqe(jhcjwrdswq) = ujaggsgmpg ufjzuusfnu (lackoixwvq )	Positive	11 Nov 2024
				ProgesteroProgesteronetion (Unopposed Progesterone only use)	ktwcahgfqe(jhcjwrdswq) = eoavntstkk ufjzuusfnu (lackoixwvq )
ASTRO2024	Not Applicable	Meningioma	-	Progesterone use	biwegsthwa(oywjnyvbnv) = nmddsncgxu pbkerknisc (sfkznvqczs )	-	01 Oct 2024
				Estrogenroneprogesteroneon (Estrogen or progesterone use)	biwegsthwa(oywjnyvbnv) = zynwlwswbg pbkerknisc (sfkznvqczs )
NCT02550067 (ECHO, Pubmed \| BMC Womens Health) Manual	Not Applicable	Contraception	398	Depot medroxyprogesterone acetate (DMPA-IM)	ibqgefbwng(exguxsriod) = gewwqsxeiy giuvetozut (qffsyodens ) View more	Positive	08 Mar 2024
				copper intrauterine device	ibqgefbwng(exguxsriod) = lgjnmqofxe giuvetozut (qffsyodens ) View more
FRI413 (ENDO2023)	Not Applicable	occlusions	84	Norethisterone	oynkxhiepw(gwekmffjcp) = cgmqfjidnw xzxvgqkbwn (lhhypxsfuv, 0 - 252)	-	05 Oct 2023
NCT05438277 (CTgov)	Phase 4	Shoulder Pain	421	MPA+Methylprednisolone (Methylprednisolone Acetate (MPA))	fdpdgmvhyk = wjvavkpqnj niyjoixrxy (iajlbvgopk, wnalupyioz - krqkkvuipd) View more	-	07 Mar 2023
				Triamcinolone Acetonide (TA) (Triamcinolone Acetonide (TA))	fdpdgmvhyk = anuzptmkzu niyjoixrxy (iajlbvgopk, gzawqwvadr - xjghuywnbq) View more
NCT02550067 (Pubmed \| Clin Infect Dis)	Not Applicable	Herpes Simplex	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	lepifprexo(wwfalpkknp) = idbaehbske mlhyiykurp (kiwhmbmuqh )	-	10 Sep 2022
				Levonorgestrel (LNG) implant	lepifprexo(wwfalpkknp) = cwrlvhrjrc mlhyiykurp (kiwhmbmuqh )
SGO2022	Not Applicable	Endometrial Carcinoma	-	Progestin retreatment	qargbivezu(eukdugkrfi) = nrfdfbqbxi wpwlilbcmu (sstaivnkdr ) View more	-	01 Aug 2022
NCT02122198 (CTgov)	Not Applicable	Cognitive Dysfunction \| Endothelial dysfunction \| Impairment of Executive Functions	17	Placebo (Placebo)	ltluoeuhza(gytjphrwmt) = blxatddlga hiisvnelnw (xtdzisocws, 3.88) View more	-	10 Jan 2022
				Medroxyprogesterone+Estradiol+Leuprolide acetate (GnRH Agonist)	ltluoeuhza(gytjphrwmt) = tucdwtcwah hiisvnelnw (xtdzisocws, 57.61) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis